hackint0sh/New-Dataset huggingface dataset:
The HidHyCo could be present in a not negligible percentage of osteopenic/osteoporotic patients. In these patients, osteoporosis and, if present, other comorbidities can improve by the surgical resection of the adrenal or pituitary adenoma if feasible, or by the use of drugs able to modulate cortisol secretion or glucocorticoid sensitivity. Moreover, the case-finding could be reserved in those patients at higher risk of having HidHyCo, therefore, reducing the costs of a scarcely specific mass screening. conditions: Osteoporosis conditions: Bone Fracture conditions: Cortisol Excess studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 1500 type: ESTIMATED measure: Prevalence of hidden hypercortisolism in osteoporosis measure: Statistical comparison of the clinical and biochemical characteristics of osteoporotic/osteopenic patients with HidHyCo and those without HidHyCo to identify the characteristics predictive of the presence of HidHyCo in osteoporosis measure: Further investigation of bone turnover in HidHyCo patients, as assessed by serum osteocalcin, CrossLaps, bone alkaline phosphatase and amino-terminal propeptide of type 1 procollagen (P1NP) and additional new potential serum markers of bone status. measure: Further investigation of bone quality as assessed by Radiofrequency Echographic Multi Spectrometry (REMS) measure: Characterization of HidHyco patients from a molecular and genetic point of view by the determination of circulating microRNAs, peripheral glucocorticoid activity and the polymorphic variants of the 11ßHSD1, GR and B2AR gene. measure: Assessment of gut microbiome composition by the analysis of fecal samples sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliera Universitaria Policlinico "G. Rodolico-San Marco" status: NOT_YET_RECRUITING city: Catania country: Italy name: Agostino Gaudio, Professor role: CONTACT lat: 37.49223 lon: 15.07041 facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan country: Italy name: Cristina Eller-Vainicher, MD role: CONTACT name: Giorgia Grassi, MD role: SUB_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: Istituto Auxologico Italiano IRCCS status: RECRUITING city: Milan country: Italy name: Elisa Cairoli, MD role: CONTACT name: Carmen Aresta, MD role: SUB_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: Ospedale "Casa Sollievo della Sofferenza" IRCCS status: RECRUITING city: San Giovanni Rotondo country: Italy name: Alfredo Scillitani, MD role: CONTACT name: Flavia Pugliese, MD role: SUB_INVESTIGATOR lat: 41.70643 lon: 15.7277 facility: Azienda Ospedaliera Universitaria Senese status: NOT_YET_RECRUITING city: Siena country: Italy name: Luigi Gennari, Professor role: CONTACT lat: 43.31822 lon: 11.33064 hasResults: False
nctId: NCT06324071 id: 2022_TSOD_125 briefTitle: Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility overallStatus: RECRUITING date: 2024-01-08 date: 2025-01 date: 2025-04 date: 2024-03-21 date: 2024-03-22 name: Fitoplancton Marino, S.L. class: INDUSTRY name: Fundacio Clinic Barcelona name: Fertypharm briefSummary: TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). In a previous pilot trial, the ability of TetraSOD® (dose: 250 mg/day) to improve semen characteristics in idiopathic infertile men after three months of treatment was assessed, revealing significant improvements in almost all of the analyzed parameters. In a further clinical trial close to finish (ClinicalTrials.gov Identifier: NCT04864314) using the same dose, such positive results have been tested again in a higher number of patients, and additional parameters have been included in order to gain insights into the sperm physiological changes that underpin the improvement in semen quality. In this new clinical trial, an intermediate dose (125 mg/day) is going to be tested in an attempt to determine a range of TetraSOD® dosage being clinically active for the treatment of male infertility. conditions: Male Infertility studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 50 type: ESTIMATED name: Sham name: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity measure: Sperm motility measure: Sperm concentration measure: Sperm oxidative stress measure: DNA integrity measure: sORP by MiOXSYS measure: Adverse effects sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Hospital Clinic status: RECRUITING city: Barcelona zip: 08036 country: Spain name: Juan M Corral role: CONTACT phone: +34 932275545 email: jmcorral@clinic.cat name: Meritxell Jodar role: CONTACT phone: +34 932275510 email: mjodar@clinic.cat name: Marta Guimerà role: SUB_INVESTIGATOR name: Juan M Mayorga-Torres role: SUB_INVESTIGATOR name: Antonio Alcaraz role: SUB_INVESTIGATOR name: Dolors Manau role: SUB_INVESTIGATOR name: Rafael Oliva role: SUB_INVESTIGATOR lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06324058 id: Huashan_H briefTitle: Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2025-03-18 date: 2026-03-18 date: 2024-03-21 date: 2024-03-21 name: Huashan Hospital class: OTHER briefSummary: This trial plans to enroll 190 eligible patients and randomize them into two groups with a 1:1 ratio, with 95 patients in each group. The experimental group will receive immediate cryoablation therapy at the resection site after TUR, while the control group will only undergo TUR and receive conventional BCG instillation therapy postoperatively. Both groups of subjects will undergo Re-TURBT or cystoscopy 10-12 weeks after surgery to compare the tumor-free residual rates and adverse events between the two groups. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 190 type: ESTIMATED name: Transurethral cryoablation name: Transurethral resection of bladder tumor name: Bcg Intravesical measure: Tumor residual rate measure: Recurrence measure: Progression sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06324045 id: MRC-01-22-314 briefTitle: Deprescribing Intervention for Patients With Chronic Kidney Disease overallStatus: RECRUITING date: 2024-02-19 date: 2025-08-31 date: 2025-08-31 date: 2024-03-21 date: 2024-03-21 name: Hamad Medical Corporation class: INDUSTRY name: Qatar University name: Winchester District Memorial Hospital briefSummary: Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented.
In general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes. conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: CKD patients will be screened using medical records. Eligible patients will be approached during their routine visits to FBJ Kidney Center and other ambulatory kidney centers. Due to feasibility and practicality issues, selecting the patients will be consecutive case series as per their availability during the time of the recruitment (nonprobabilistic).
After obtaining informed consent, patients will be randomized into one of the two study arms. Randomization will be stratified by dialysis dependency (dialysis vs. pre-dialysis); randomly permuted balanced block sizes of 4 for dialysis patients and 1 for pre-dialysis will be used. Neither the practitioners nor the patients will be blinded to the patients' allocated groups due to the nature of the intervention. Due to feasibility and practicalities, selecting the patients will be consecutive as per their availability during the time of the recruitment (non-probabilistic). primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 424 type: ESTIMATED name: Deprescribing measure: Percentage of participants with at least one Potentially inappropriate medications (PIMs) measure: Number of Potentially inappropriate medications (PIMs) measure: Pill burden measure: Health-related quality of life (HRQoL) measure: Treatment burden measure: Self-reported adherence measure: Medication Refills adherence measure: Emergency department visits and hospitalizations measure: Unanticipated adverse effects measure: Cost avoidance measure: Cost savings sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hamad Medical Corporation status: RECRUITING city: Doha state: Unlisted (UL) zip: 00000 country: Qatar name: Abdulla Hamad, MD role: CONTACT phone: +97444394804 email: ahamad9@hamad.qa name: Rania Ibrahim, MSc. role: CONTACT phone: +9744394808 email: ribrahim4@hamad.qa name: Abdulla Hamad, MD role: PRINCIPAL_INVESTIGATOR name: Ahmed Awaisu, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Daoud Al-Badriyeh, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Muhammad Abdul Hadi, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Ali Elbeddini, Pharm D role: SUB_INVESTIGATOR name: Rania Ibrahim, MSc. role: SUB_INVESTIGATOR name: Amani Zidan, MSc. role: SUB_INVESTIGATOR name: Kheloud Khaled, Pharm D role: SUB_INVESTIGATOR lat: 25.28545 lon: 51.53096 hasResults: False
nctId: NCT06324032 id: 021-FPO20 briefTitle: SUNNYDAY: SUbepithelialgastroiNtestiNal Tumors Detection,accuracYDiAgnosis,ElastographY and Contrast-enhanced EUS acronym: SunnyDay021 overallStatus: RECRUITING date: 2020-12-17 date: 2025-06-30 date: 2025-12-31 date: 2024-03-21 date: 2024-03-21 name: Fondazione del Piemonte per l'Oncologia class: OTHER briefSummary: This will be a longitudinal, prospective, observational multicenter study where the role of EUS-E will be examined in differentiating subepithelial gastrointestinal tumors in 138 patients conditions: Subepithelial Gastrointestinal Tumors studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 138 type: ESTIMATED name: EUS Elastography (EUS-E) measure: Evaluation of EUS-E accuracy qualitative measure: Evaluation of EUS-E accuracy quantitative measure: Evaluation of diagnostic accuracy of EUS-biopsy with fine needle biopsy (FNB) measure: Evaluation of gene mutations in EUS-guided specimen measure: Correlation of elastographic and contrastographic characteristics of SETs with the pathological risk stratification. measure: Complication rate (perforations, bleeding) of the procedure sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Santa Maria della Scaletta status: RECRUITING city: Imola state: Bologna country: Italy name: Pietro Fusaroli, MD role: CONTACT lat: 44.35916 lon: 11.7132 facility: Istituto Clinico Humanitas status: RECRUITING city: Rozzano state: Milano country: Italy name: Silvia Carrara, MD role: CONTACT lat: 45.38193 lon: 9.1559 facility: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo status: RECRUITING city: Candiolo state: Turin, zip: 10060 country: Italy name: Teresa Staiano, MD role: CONTACT phone: +390119933413 email: teresa.staiano@ircc.it lat: 44.95858 lon: 7.59812 facility: Ospedale Humanitas Mater Domini status: RECRUITING city: Castellanza state: Varese country: Italy name: Benedetto Mangiavillano, MD role: CONTACT lat: 45.61079 lon: 8.89616 facility: AOU Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Pietro Occhipinti, MD role: CONTACT lat: 45.44694 lon: 8.62118 facility: Istituto Oncologico Veneto status: RECRUITING city: Padova country: Italy name: Alberto Fantin, MD role: CONTACT lat: 45.40797 lon: 11.88586 facility: AOU Città della Salute e della Scienza di Torino, Ospedale Molinette status: RECRUITING city: Turin zip: 10126 country: Italy name: Claudio G. De Angelis, MD role: CONTACT lat: 45.07049 lon: 7.68682 hasResults: False
nctId: NCT06324019 id: Ethics number E.405221 briefTitle: Gynaecological Examination Gown and Patient Satisfaction overallStatus: COMPLETED date: 2022-02-01 date: 2022-04-30 date: 2022-06-22 date: 2024-03-21 date: 2024-03-21 name: ayşegül muslu class: OTHER briefSummary: The attitude of the health personnel before, during and after the examination and the positive examination experience of the person have a significant impact on ensuring the continuity of the subsequent examination and increasing the quality of the service provided. The use of different clothes in the patient during the examination will ensure that the patient\'s physical privacy is ensured from the moment of application, during diagnosis and treatment, and that the examination experience will be positively affected by preventing the use of additional covers to protect the privacy of all patients during examination and intervention. This will contribute to the maintenance of health by eliminating the intense stress and embarrassment experienced by patients during the examination and ensuring that they regularly attend health checks. In addition, meeting the privacy expectations of the patients will ensure that they are satisfied with the health service they receive, thus increasing the quality of the health service provided.
The attitude of the health personnel before, during and after the examination and the positive examination experience of the person have an important effect on ensuring the continuity of the subsequent examination and increasing the quality of the service provided. With the examination suit, it will be ensured that the patient\'s bodily privacy is ensured from the moment of application, during diagnosis, treatment and care, the use of the same cover to protect the privacy of all patients during examination and intervention will be prevented to prevent infection transmission and the examination experience will be positively affected. Thus, the intense stress and embarrassment experienced by patients during the examination will be eliminated and will contribute to the maintenance of health through regular visits to health checks. In addition, meeting the privacy expectations of patients will ensure that they are satisfied with the health service they receive, thus increasing the quality of the health service provided. In order to ensure patient privacy, to protect and improve women\'s health and to provide convenience in gynecological examination, the gynecological examination garment to be used in the examination can be designed as disposable, perineum and thigh open for the examination to be performed. In order to protect privacy, extra parts can be used to ensure that the open parts remain closed outside the examination process. Properties of the fabric used in the examination garment;
The study was carried out as a post-test control group design from randomised controlled studies. The intervention group of the study was dressed in gynaecological examination clothes, while the control group used the drape given to the patient during the examination, which is a routine practice in the health institution where the study was conducted. conditions: Gynecology conditions: Gynecology/Obstetrics Conditions studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study was carried out as a post-test control group design from randomised controlled studies. The intervention group of the study was dressed in gynaecological examination clothes, while the control group used the drape given to the patient during the examination, which is a routine practice in the health institution where the study was conducted.
H1: There is a difference between the satisfaction perception of women in the experimental group and the control group. primaryPurpose: OTHER masking: NONE count: 150 type: ACTUAL name: putting on an examination gown measure: Gynaecological examination gown sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: EGE city: İzmir state: Konak country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06324006 id: DCT3934 briefTitle: A Phase 1 Trial of LIB-01 in Healthy Participants. overallStatus: ACTIVE_NOT_RECRUITING date: 2023-08-25 date: 2024-05-30 date: 2024-05-30 date: 2024-03-21 date: 2024-03-27 name: Dicot AB class: INDUSTRY briefSummary: The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are:
* Blood sampling for laboratory parameters and pharmacokinetic analysis conditions: Erectile Dysfunction studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a Phase I, double-blind, parallel-group, placebo-controlled, randomized first-in-human trial. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 64 type: ACTUAL name: LIB-01 name: Placebo measure: To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following a single oral dose of LIB-01. measure: To evaluate changes in vital signs in healthy male participants, following a single oral dose of LIB-01. measure: To evaluate changes in ECG in healthy male participants, following a single oral dose of LIB-01. measure: To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following multiple oral dosing of LIB-01. measure: To evaluate changes in vital signs in healthy male participants, following a multiple oral dosing of LIB-01. measure: To evaluate changes in ECG in healthy male participants, following multiple oral dosing of LIB-01. measure: To characterise the maximum plasma concentration of LIB-01, following a single oral dose. measure: To characterise the plasma concentration half life of LIB-01, following a single oral dose. measure: To characterise the plasma concentration area under curve of LIB-01, following a single oral dose. measure: To characterise the maximum plasma concentration of LIB-01 following multiple oral dosing. measure: To characterise the plasma concentration half life of LIB-01 following multiple oral dosing. measure: To characterise the plasma concentration half life of LIB-01 following multiple oral dosing. sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Trial Consultants city: Uppsala zip: 75237 country: Sweden lat: 59.85882 lon: 17.63889 hasResults: False
nctId: NCT06323993 id: 2021-115 briefTitle: The Effect of Different Window-preparation Approaches on the Clinical Outcomes of Lateral Sinus Floor Elevation overallStatus: COMPLETED date: 2022-03-01 date: 2022-05-01 date: 2023-06-15 date: 2024-03-21 date: 2024-03-21 name: The Dental Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: This study retrospectively evaluated the effect of two different lateral window preparation techniques on peri-implant bone augmentation for patients who underwent lateral sinus floor elevation with simultaneous implant placement using two-dimensional and three-dimensional radiographic results, with special emphasis placed on the stability of the graft material after surgery. conditions: Dental Implantation conditions: Cone-Beam Computed Tomography conditions: Surgical Procedure, Unspecified conditions: Maxillary Sinus Floor Augmentation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 34 type: ACTUAL name: Piezoelectric osteotomy measure: Apical bone height measure: Endo-sinus bone gain measure: Palatal bone height measure: Buccal bone height measure: Augmentation volume measure: Perforation incidence measure: Early implant loss measure: Lateral window length measure: Lateral bone length sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine city: Hangzhou state: Zhejiang zip: 310000 country: China lat: 30.29365 lon: 120.16142 hasResults: False